Roth Capital Lifts PT on Ligand (LGND) 32% Ahead of Q3 Results
Tweet Send to a Friend
Roth Capital boosts its price target on Ligand Pharmaceuticals (Nasdaq: LGND) from $92 to $121.50 and maintains a Buy rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
